Why Is RAPPORT THERAPEUTICS Equity (RAPP) Stock Down Today?

RAPP stock is down 17.70% to $34.13 as the CEO's presentation at the TD Cowen Neuropsychiatry Summit appears to have triggered a sharp selloff. The stock's decline coincided with a broader slump in biotech names, with RAPP among the hardest-hit. Recent insider selling and mixed analyst coverage have added to the downward pressure.

What Happened

Rapport Therapeutics CEO presented at the TD Cowen Neuropsychiatry Summit, which led to a significant drop in the stock. The presentation likely raised questions about the company's progress or the outlook for its RAP-219 Phase II trial in bipolar mania. The stock's decline occurred amid a broader downturn in biotech stocks, with several names falling sharply. The Fly reported that the stock dropped after the CEO's remarks, while other outlets noted the broader sector weakness. The stock has also been impacted by recent insider transactions, with the CEO and other executives selling shares in the past month.

What The Data Shows

Over the past 8 sessions, RAPP has fallen 21.0% from $43.62 to $34.45. The stock printed 67 fresh 52-week lows on September 23, indicating broad retail and institutional pessimism. Insider filings show 9 sell transactions totaling $7.5 million in the last 90 days, with the most recent on September 9. The stock's fundamentals remain unprofitable, with an EPS TTM of -3.05 and a beta of 1.03. The 52-week range of $23.75 to $52.93 shows a wide trading band, but the recent move has pushed it closer to the lower end.

What To Watch

Rapport Therapeutics has no upcoming earnings date listed. Investors should monitor the breadth of coverage and any new analyst ratings as the company approaches its pivotal RAP-219 Phase II data.